NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Nanobiotix S.A. (NBTX) Stock Analysis

Nanobiotix S.A. (NBTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NBTX

$38.80

−$1.20 (−3.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NBTX with… →

NBTX Key Statistics

As of Sep 4, 2026
Trading
Open
$39.01
Previous Close
$40.00
Day's Range
38.43–40.99
52-Week Range
8.41–57.14
Volume
119.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.57
Valuation
Market Cap
$1.97B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
60.49
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.58
Financials (FY)
Revenue (FY)
$29.64M
Net Income (FY)
−$23.96M
Profit marginThe share of revenue left as profit after all costs and taxes.
−73.52%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
50.81M
1-Year Return
+355.19%
Dividend and dates
Earnings Date
September 29, 2026estimated
Avg Volume
131.04K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NBTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+67.82%
2025+705.57%
2024−60.58%
2023+98.37%
2022−54.69%
2021−50.91%
2020 (partial year)−2.83%

As of September 4, 2026.

NBTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$29.64M−$23.96M−80.8%
2024−$11.61M−$68.13M586.8%
2023$30.06M−$39.70M−132.1%
2022$0.00−$57.04M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$29.64M—−$10.82M−$23.96M−80.8%
2024−$11.61M—−$68.39M−$68.13M586.8%
2023$30.06M—−$26.78M−$39.70M−132.1%
2022$0.00—−$46.70M−$57.04M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NBTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricNBTXBiotechnology medianvs median
P/S ratio60.4915.264.0x the median
Profit margin−73.52%0.00%73.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Nanobiotix S.A. (NBTX) is capitalised at $1.97B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 100.

The most recent close on file for NBTX is $38.80, dated September 4, 2026. That is −$1.20 (−3.00%) against the previous close. The 52-week range on file runs from $8.41 to $57.14. The latest close sits 361.36% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $29.64M. The same year closed with a net loss of $23.96M. The reported profit margin is −73.52%. That is 73.5 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.58.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $29.64M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 60.49 times revenue. On price-to-sales that is 4 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +355.19%. Measured over 5 years, that is +22.74% a year compounded. Beta against the wider market is reported at 0.57. Annualized volatility over the trailing 5 years is 137.15%.

Growth & Income

No dividend is on file for NBTX.

2026 is still running; the price is +67.82% year to date. Across the complete calendar years on file, 2025 returned +705.57% and 2024 returned −60.58%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Nanobiotix S.A. (NBTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nanobiotix S.A. NBTX $1.97B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Nanobiotix S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nanobiotix S.A.

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Visit website →